Please login to the form below

Not currently logged in
Email:
Password:

Vosevi

This page shows the latest Vosevi news and features for those working in and with pharma, biotech and healthcare.

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi

Gilead wins European approval for triple hep C combination Vosevi. The treatment brings together sofosbuvir, velpatasvir and voxilaprevir. ... The results show that 97% of patients on Vosevi achieved the primary efficacy endpoint of a sustained viral

Latest news

  • Gilead gets OK for three-in-one hep C therapy in US Gilead gets OK for three-in-one hep C therapy in US

    The US FDA has approved Gilead Sciences' triple drug therapy Vosevi to treat hepatitis C Virus (HCV) as a back-up therapy for patients who can't eliminate the virus with ... The FDA has cleared the new product for all the most common HCV genotypes (1-6)

  • Samsung Bioepis wins CHMP nod for second Humira biosimilar Samsung Bioepis wins CHMP nod for second Humira biosimilar

    virus (infection) - AbbVie's Maviret (glecaprevir/pibrentasvir) and Gilead's Vosevi (sofosbuvir/velpatasvir/voxilaprevir). ... The CHMP notes that "both Maviret and Vosevi are active against all genotypes of the virus and with some differences between

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Clark Health Communications

Clark Health Communications (CHC) is an independent, award-winning health and medical communications agency. Our collaboration with experts and advocates enhances...

Latest intelligence

No Voice, No Choice
Adelphi Research UK’s insights help to campaign for change in the Mental Health Act...
Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...

Infographics